Recent progress in drug delivery systems for anticancer agents
- 1 June 2002
- journal article
- review article
- Published by Springer Science and Business Media LLC in Archives of Pharmacal Research
- Vol. 25 (3), 229-239
- https://doi.org/10.1007/bf02976620
Abstract
Recent progress in understanding the molecular basis of cancer brought out new materials such as oligonucleotides, genes, peptides and proteins as a source of new anticancer agents. Due to their macromolecular properties, however, new strategies of delivery for them are required to achieve their full therapeutic efficacy in clinical setting. Development of improved dosage forms of currently marketed anticancer drugs can also enhance their therapeutic values. Currently developed delivery systems for anticancer agents include colloidal systems (liposomes, emulsions, nanoparticles and micelles), polymer implants and polymer conjugates. These delivery systems have been able to provide enhanced therapeutic activity and reduced toxicity of anticancer agents mainly by altering their pharmacokinetics and biodistribution. Furthermore, the identification of cell-specific receptor/antigens on cancer cells have brought the development of ligand- or antibody-bearing delivery systems which can be targeted to cancer cells by specific binding to receptors or antigens. They have exhibited specific and selective delivery of anticancer agents to cancer. As a consequence of extensive research, clinical development of anticancer agents utilizing various delivery systems is undergoing worldwide. New technologies and multidisciplinary expertise to develop advanced drug delivery systems, applicable to a wide range of anticancer agents, may eventually lead to an effective cancer therapy in the future.Keywords
This publication has 87 references indexed in Scilit:
- Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumorsCancer, 2001
- Liposomes as sustained release system for human interferon-γ: biopharmaceutical aspectsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2001
- Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cellsGene Therapy, 2000
- Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to ratsPharmacological Research, 2000
- Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiencyImmunology & Cell Biology, 2000
- Folic Acid Targeting of Protein Conjugates into Ascites Tumour Cells from Ovarian Cancer PatientsJournal of Drug Targeting, 2000
- A Possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrierEuropean Journal Of Cancer, 1999
- Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal TissuesJapanese Journal of Cancer Research, 1998
- The design and development of DaunoXome® for solid tumor targeting in vivoAdvanced Drug Delivery Reviews, 1997
- Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogsAnti-Cancer Drugs, 1994